AoU Research Priorities Use Cases

Do specific diabetes drugs increase the risk of peripheral artery disease, a diabetic foot ulcer or an amputation?

A major advance in diabetes treatment is the finding that specific glucose-lowering drugs reduce the risk of cardiovascular disease. The results were tempered by the increased risk of amputations for the groups that received the SGLT2 inhibitor, canagliflozin. The generalizability of this finding is unknown. An understanding of the association of specific diabetes drugs with lower extremity complications will allow a better assessment of the risks and benefits for individual patients.

Keywords

Voting

10 votes
Ideate
Idea No. 458